Abstract
The pharmacologic and physiologic effects of the slow-channel calcium antagonists verapamil, nifedipine and diltiazem are reviewed. Relevant pathophysiologic features of various acute ischemic heart disease syndromes are also reviewed and the clinical applications of the slow-channel calcium antagonists to acute ischemic heart disease syndromes in patients are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
